ROCKVILLE, Md.–(BUSINESS WIRE)–20/20 GeneSystems, Inc. announced today that it will offer in its CLIA laboratory a COVID-19 antibody test that received an Emergency Use Authorization (EUA) from the FDA on May 3. According to test manufacturer Roche Diagnostics, the blood test has a specificity greater than 99.8% and sensitivity of 100% (14‑days post-PCR confirmation) and is used to determine if a person has developed antibodies to SARS-CoV-2, the virus that causes COVID-19.
{iframe}https://www.businesswire.com/news/home/20200518005682/en/%C2%A02020-GeneSystems-Provide-Newly-FDA-Authorized-COVID-19{/iframe}